Making the Invisible Visible
Our Digital Biomarker Platform
nQ Cortex is a Digital Biomarker Platform that can be adapted across disorders and readied for rapid scaling. The AI-powered computational biomarkers yield powerful insights from passively collected real world data to drive real world insights.
The nQ platform is an integrated solution for brain health screening and monitoring, with products designed for use in research, clinical care and daily life. nQ uses digital devices and machine learning algorithms to deliver powerful insights quickly, affordably, and objectively.
The nQ platform is an integrated solution for brain health screening and monitoring, with products designed for use in research, clinical care and daily life. nQ uses digital devices and machine learning algorithms to deliver powerful insights quickly, affordably, and objectively.
We believe that the way our fingers interact with smart phones and computers can reveal the presence of certain neuromotor and neurocognitive conditions like:
Clinical Research Studies
The potential of our technology has been shown through clinical research studies conducted at MIT and later with the support of the Michael J. Fox Foundation, the Cleveland Clinic, and Massachusetts General Hospital.
What We Do
We examine how the kinematics of typing on touchscreen and mechanical devices can be used for pragmatic medical and research applications bringing Real World Evidence to patients, caregivers, and clinicians in a passive manner.
How it Works
Passive, continuous, remote monitoring of typing interactions on personal devices is becoming increasingly relevant and utilized in the diagnosis and management of neurological diseases.
Passive monitoring is advantageous because it eliminates burden from the individual (e.g., fewer office visits and invasive diagnostic procedures), allowing them to focus on quality of life while contributing to their clinical management.
For Researchers
nQ’s app allows for a greater collection of clinically relevant information for assessing safety and efficacy of pharmacologic and medical device interventions, improving the efficiency of both research and development.
For Clinicians
nQ's app creates a more complete picture of disease progression, allowing for small changes to be caught early. This allows for earlier and more targeted interventions, increasing likelihood of improved patient outcomes.
This information can be used for targeted patient recruitment and selection, more efficient evaluation of pharmacologic and medical interventions both in development and post approval, and long-term studies of disease modifying agents. The full range of practical applications for a cost effective, highly scalable digital solution is massive and rapidly evolving.
Key Advantages of nQ’s Computationally-Derived Digital Biomarkers
Passive, continuous, remote monitoring of typing interactions on personal devices is becoming increasingly relevant and utilized in the diagnosis and management of neurological diseases.
Passive monitoring is advantageous because it eliminates burden from the individual (e.g., fewer office visits and invasive diagnostic procedures), allowing them to focus on quality of life while contributing to their clinical management.
Real-World Quantification:
Continuous, longitudinal, remote, real-world quantification of psychomotor symptoms.
Ease for Patients:
Patients are not burdened with completing structured tasks or clinic visits for data collection. Patients use their personal devices as they normally would, and data is collected passively and transparently, often 24/7.
Data Security:
Patient privacy and security are ensured at each step of the algorithm. Biomarkers perform even though the content of what patients type on their personal devices is kept confidential and secure.
Use cases for nQ Medical's device post FDA clearance:
- Disease screening for diagnostic referral and clinical trial recruitment/development;
- Symptom monitoring as an independent or companion software to aid treatment titration, monitor compliance;
- Collect real-world data (RWD) and generate real-world evidence (RWE);
- Supporting telehealth visits, access to patients in under-served/remote areas via telemetry.
